Biosimilars Market

The expiry of patents and regulatory exclusivity for blockbuster biologic medicines is a major driver of the biosimilars market, as it creates opportunities for biosimilar manufacturers to enter large, established therapeutic markets. Several high-value biologics have either recently lost exclusivity or are approaching the end of their market protection, creating substantial commercial opportunities for biosimilar developers. Notable examples include adalimumab (Humira), ustekinumab (Stelara), denosumab (Prolia/Xgeva), aflibercept (Eylea), pembrolizumab (Keytruda), nivolumab (Opdivo), and daratumumab (Darzalex). The expiration of protection for these products is particularly significant because they have established large patient populations, extensive physician familiarity, and substantial annual sales, allowing biosimilar manufacturers to enter markets with an already validated demand base. For example, the US market experienced significant biosimilar activity following the loss of exclusivity of Humira, with multiple adalimumab biosimilars entering the market and intensifying price and market-share competition.

Intensifying competition among multiple biosimilar manufacturers is creating significant downward pressure on prices and limiting the revenue potential of individual biosimilar products. Once a high-value biologic loses exclusivity, several manufacturers may launch competing biosimilars within a relatively short period, resulting in discounts, tender competition, formulary negotiations, and contracting pressure. This effect has been particularly evident for adalimumab (Humira) in the US, where numerous biosimilar versions entered the market following loss of exclusivity, resulting in substantial price competition and differentiated contracting strategies. Similar competitive pressure is expected as multiple biosimilars of ustekinumab (Stelara), denosumab (Prolia/Xgeva), aflibercept (Eylea), and other blockbuster biologics enter major markets.

The upcoming loss of patent protection and regulatory exclusivity for a new generation of high-value biologics represents one of the largest long-term opportunities for biosimilar market expansion. After the first wave of biosimilars focused heavily on products such as adalimumab, trastuzumab, rituximab, and infliximab, the market is entering a second wave involving several high-revenue biologics across oncology, immunology, ophthalmology, hematology, and rare diseases. Important opportunities include pembrolizumab (Keytruda), nivolumab (Opdivo), daratumumab (Darzalex), ocrelizumab (Ocrevus), dupilumab (Dupixent), aflibercept (Eylea), denosumab (Prolia/Xgeva), and risankizumab (Skyrizi). These products have large established patient populations and generate billions of dollars in annual reference-product sales, making them attractive targets for biosimilar developers.

The increasing number of pharmaceutical and biotechnology companies entering the biosimilars market is intensifying competition for the same reference biologic, creating significant challenges in achieving sustainable market share and profitability. As blockbuster biologics lose exclusivity, multiple developers often initiate biosimilar programs several years in advance, resulting in several competing products reaching regulatory approval within a relatively short period. This trend is particularly evident for commercially attractive molecules such as adalimumab, ustekinumab, denosumab, aflibercept, bevacizumab, trastuzumab, and ranibizumab, where multiple biosimilars compete for the same patient population. Competition is not limited to price, as manufacturers increasingly differentiate through launch timing, interchangeability, supply reliability, contracting, patient-support programs, device configurations, and geographic coverage.